Latest news with #clinical trials
Daily Mail
12 hours ago
- Health
- Daily Mail
The 'unbeatable' cell-signalling hair loss treatment that delivers results in SIX weeks: 'My hair line is filling in'
Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more A research-driven advanced hair system designed to optimise hair follicle function is producing noticeable improvements in just six weeks, with users saying it 'actually works'. The Calecim Advanced Hair System is a six-week hair restoration program supported by clinical trials, which reveal visible results in just six weeks. And it's had the backing of loyal users too. Calecim Advanced Hair System The Calecim Advanced Hair System is a six-week hair restoration program that uses an active ingredient PTT-6 to harness the body's natural mechanisms of regeneration. Research has shown that this stem-cell-based ingredient supports the optimal function of hair follicles, addresses thinning to improve scalp health, and increases hair volume and density. £295 Shop Formulated to spur new growth and leave your hair thicker and fuller over the course of six weeks, the stem cell formula essentially reactivates your follicles, signalling to them that it's time to begin regenerating new strands Helping to stimulate hair growth by activating the hair follicles, and managing signs of inflammation that cause hair shedding, it's one to have on your radar if you're battling hair thinning. The market is saturated with lotions and potions touted as a solution to thinning, dry and brittle hair, but in reality, many are not backed up by solid scientific evidence. The Calecim Advanced Hair System is an evidence-based cell-signalling hair loss treatment that uses an active ingredient PTT-6 to harness the body's natural mechanisms of regeneration. Combining derma-stamp microneedling with Calecim Professional's hair serum, it contains over 3,000 proteins, including growth factors, cytokines and exosomes that signal cells to regenerate, which in this case encourages the growth of new hair. While there isn't a cure for hair loss, there are effective medications and hair restoration treatments like the Calecim Advanced Hair System that have been proven effective when used consistently over time. The Calecim topical serum has been used by men and women with thinning hair and can be applied to the scalp at home or in a clinical setting. Unlike a lot of hair growth treatments, this has been supported by clinical trials, which revealed visible results in just six weeks. Better still, the pink-looking product, which is applied directly to the scalp for maximum efficacy, was also found to have produced thicker hair after 12 weeks. As it triggers your own stem cells that sit within the hair follicles, many have found you'll get less inflammation, which is an underlying cause of many types of hair loss. The process also accelerates follicle cell growth for better length and volume, too. As well as impressing in clinical trials, shoppers who have faced challenges with their hair have left increasingly positive reviews for the Calecim Advanced Hair System too. And while an investment priced at £295, the at-home treatment has had the backing time and time again by loyal users who hail it 'unbeatable'. 'Calecim is unbeatable. The one and only product that works on growing new and improving density. Absolute gem', raved one user. Another agreed, adding: 'I found Calecim growth products and am happy that I did. I no longer have the bald patches that were in the front of my line. I love the way my hair line is filling in and hope that the bald patches will continue to keep filling in with this product. Thank you for giving my confidence back.' To use, the brand recommends applying twice a week with the derma stamper, using half an ampoule each treatment, and one ampoule each week. One box of ampoules will last six weeks.
Medscape
3 days ago
- Health
- Medscape
5-Grass SLIT Shows Benefit in Allergic Rhinoconjunctivitis
TOPLINE: Five-grass-pollen liquid sublingual immunotherapy (SLIT) reduced symptoms and the need for medications to treat symptoms in patients with allergic rhinoconjunctivitis (ARC) with or without asthma — while maintaining a favorable safety profile and providing consistent benefits across ages, comorbidities, and treatment durations. METHODOLOGY: Researchers conducted a systematic review and meta-analysis to evaluate the efficacy of five-grass-pollen liquid SLIT in patients with ARC with or without asthma. Nine studies comparing the efficacy of interventional immunotherapy with that of placebo in this population were included. The key outcomes comprised symptom severity, assessed as the symptom score; a reduction in medication use, assessed as the medication score; and the incidence of adverse events (AEs). TAKEAWAY: A pooled analysis of eight studies showed a significant reduction in symptom score in the interventional immunotherapy group vs the placebo group (standardized mean difference [SMD], -0.34; 95% CI, -0.62 to -0.06; P < .05) over a mean follow-up of 19 months. Analysis of data pooled from six studies showed a significant reduction in use of drugs for symptoms in the interventional immunotherapy group vs the placebo group (SMD, -0.54; 95% CI, -0.97 to -0.10; P < .05) over a mean follow-up of 20 months. AEs occurred in 20.6% of participants in the interventional immunotherapy group vs 17.5% in the placebo group (P = .46), with treatment discontinuation rates due to AEs of 3.0% and 1.8%, respectively (P = .41). Treatment efficacy remained consistent regardless of cumulative dose, treatment duration, or asthma status. IN PRACTICE: '[The findings] suggest that the dose of five-grass SLIT-liquid can be safely adjusted for better adverse event management without compromising treatment outcomes,' the authors of the study wrote. 'This flexibility makes it possible to tailor treatment according to the patient's condition while addressing their needs and expectations,' they added. SOURCE: Danilo Di Bona, with the University of Foggia, Foggia, Italy, was the corresponding author of the study, which was published online on July 17 in the Journal of Investigational Allergology and Clinical Immunology. LIMITATIONS: The analysis had a relatively small sample size, variation in dosages and treatment durations across studies, and incomplete reporting of AEs in some studies. DISCLOSURES: This study was funded by Stallergenes Greer, a pharmaceutical company. One author declared receiving fees from this company. Some authors reported receiving consulting fees; payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events; or support for attending meetings or travel and serving on data safety monitoring boards or advisory boards for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
22-07-2025
- Business
- Yahoo
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an 'Outperform' rating and a $5 price target. The research firm remains confident about the company's long-term prospects following its pivot from an antibody discovery platform to one that develops its internal pipeline. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Leerink Partners is especially bullish about the company's upcoming programs ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. The two programs are scheduled to enter Phase 1 clinical trials in the third quarter of 2025. The research firm also pointed out that AbCellera's existing antibody discovery collaborations are well-positioned to deliver long-term value. It expects the company to benefit from milestone payments and royalties as it leverages antibody capabilities towards a pipeline focused on validated targets. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that focuses on discovering and developing antibody-based medicines. It leverages a proprietary, AI-powered technology platform to search, decode, and analyze natural immune systems, identifying antibodies that can be developed into potential drugs. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
21-07-2025
- Health
- Medscape
TNT Shows Similar Efficacy Across Regimens in Rectal Cancer
TOPLINE: In a multicentre study of patients with locally advanced rectal cancer, substantial variation existed in the choice of total neoadjuvant therapy (TNT), but efficacy was comparable across different regimens and consistent with that reported in clinical trials. METHODOLOGY: Researchers conducted an international, multicentre study in 21 countries and included 1585 patients (median age, 61 years; 37.1% women) with stage II/III rectal adenocarcinoma from September 2012 to December 2023. The primary objective focused on the type of TNT administered depending on the regimen, timing and type of chemotherapy, and type of radiotherapy. Secondary objectives encompassed safety and efficacy overall and on the basis of the type of TNT after propensity vector matching. Efficacy endpoints included pathologic complete response, complete response, local or distant progression at the time of treatment failure, event-free survival (EFS), and overall survival (OS). Overall, 17.7%, 33.4%, 12%, and 16.2% of patients were treated according to PRODIGE 23-like, RAPIDO-like, OPRA induction-like, and OPRA consolidation-like regimens, respectively. TAKEAWAY: Chemotherapy was given as induction, consolidation, and sandwich for 34.5%, 51.0%, and 14.5% of patients, respectively; regimens were single agent (1.1%), doublet (78.8%), and triplet (20.1%). Radiotherapy was delivered as short-course radiotherapy in 37.2% and long-course chemoradiotherapy in 62.8% of cases. The pathologic complete response rate was 21.3%, and the complete response rate was 23.2%; local and distant progression at the time of treatment failure were 7% and 16.2%, respectively. Three-year EFS reached 68%, and 5-year OS was 79%. In the overall population, PRODIGE 23-like regimens showed better survival outcomes than RAPIDO-like regimens (EFS: hazard ratio [HR], 0.68; P = .03; OS: HR, 0.51; P = .04), OPRA induction-like regimens (EFS: HR, 0.66; P = .04; OS: HR, 0.35; P = .003), and OPRA consolidation-like regimens (EFS: HR, 0.64; P = .02; OS: HR, 0.50; P = .05). After the propensity vector matching analysis of 928 patients (58.5%), no significant differences in survival outcomes were observed between TNT regimens. IN PRACTICE: "This case series study illuminates the applicability of TNT to clinical practice," the authors of the study wrote. "TNT decisions should be made based on the individual risk profile and following an accurate discussion about the positives and negatives of each option while considering patient preferences and expectations," they added. SOURCE: This study was led by Alessandro Audisio, MD, Université libre de Bruxelles, Institut Jules Bordet-Hôpital Erasme, Brussels, Belgium. It was published online on July 10, 2025, in JAMA Oncology. LIMITATIONS: The retrospective design of the study introduced potential data collection errors and biases, which were only partially addressed through remote monitoring and data imputation. The relatively short follow-up period may have prevented the detection of differences in long-term outcomes between TNT regimens. Additionally, variations in treatment delivery, staging methods, and supportive care across institutions complicated direct comparisons. Despite involving multiple countries, the predominant European patient population limited the generalisability of the results. DISCLOSURES: This study was sponsored by the Institut Jules Bordet and endorsed by the Oncodistinct Network. Several authors reported receiving personal fees and grants and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Reuters
19-07-2025
- Health
- Reuters
Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
July 18 (Reuters) - U.S. regulators asked Sarepta Therapeutics (SRPT.O), opens new tab on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died, but the company said it would not do so. The Food and Drug Administration announced the move, confirming an earlier Reuters report, after making the request at a meeting with Sarepta on Friday. After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy to ambulatory people but maintain a halt it implemented June 15 for non-ambulatory patients after reporting to the FDA a case of acute liver failure in a patient who could not walk. Sarepta said it made the decision "based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population." While the 51-year-old man with limb girdle muscular dystrophy who died most recently was not taking Elevidys, his experimental therapy and Elevidys are based on similar gene technology, the FDA said. The FDA said it was putting clinical trials for limb girdle muscular dystrophy on hold due to safety concerns. Elevidys received traditional approval in 2024 for patients age 4 and older with the Duchenne muscular dystrophy gene mutation who can walk, as well as accelerated, conditional approval for those with the muscle-wasting disease who cannot, even though the therapy failed to meet the main goal in a late-stage trial. In another setback, the regulator also revoked the platform technology designation for Sarepta's gene therapy, a status that can streamline regulatory review and that is given when a technology has promise across multiple indications. Sarepta shares ended down 36% at $14.08. At one point on Friday, the stock tumbled over 40% to a more than nine-year low after the company disclosed the third patient death. The agency increased scrutiny of Sarepta when two teenage boys receiving Elevidys died this year. All three of the deaths were caused by acute liver failure and occurred in non-ambulatory patients. The FDA said it is continuing to investigate the risk of acute liver failure with serious outcomes, including hospitalization and death, with gene therapies using Sarepta's AAVrh74 platform technology. Wall Street analysts have said the third death could make patients more hesitant to use Elevidys. Patient groups said the developments around Elevidys have been concerning. "Families with Duchenne muscular dystrophy are grappling with a mix of disappointment, uncertainty about choices they are making for their own children or themselves," said Debra Miller, founder of the non-profit CureDuchenne. On Wednesday, Sarepta said it was working with the FDA to add a warning label about liver toxicity risks to Elevidys' packaging. On an investor call on Friday, analysts asked Sarepta why it had not disclosed the latest patient death on Wednesday, when it announced 500 layoffs and cuts to its limb-girdle muscular dystrophy program, citing financial reasons. CEO Doug Ingram said the matter was "neither material, nor central" to Wednesday's update and the decision to end the limb-girdle muscular dystrophy gene therapy study was made independently of the patient death. The company also said liver issues were not a new safety signal in the study. However, some analysts, including those at BMO Capital Markets, warned that Sarepta's handling of the disclosure could damage management credibility. At least two analysts asked whether other deaths had occurred in Sarepta's gene therapy programs. The company said it was not aware of any beyond the three that were disclosed.
